The $1.7M investment into expertise and equipment to expand its North American capabilities was announced by SGS in September 2018. Its strategic geographic location in the northern suburbs of Chicago, within a rich cluster of biopharmaceutical companies, enables SGS to act as a local partner for innovators looking for expertise in biopharmaceutical analysis.
Dr. Jamil, who has over 25 years' experience in the life science industry, will be responsible for overseeing the newly created biologics department at the 58,000 sq. ft facility. He joins SGS from global healthcare company Fresenius Kabi, where he held the position of Senior Manager within Analytical Development.
Mark Rogers, Global Technology Director at SGS said: "Haris joins SGS at an exciting time for the company and brings a wealth of experience and leadership to SGS. We are pleased to have him play an integral part in the launch and delivery of our new biologics testing services at the facility and lead the way in ensuring outstanding service for our biopharmaceutical clients."
Dr. Jamil received his Ph.D. in Biochemistry from the University of London and has over 15 years' direct experience leading analytical development and product development laboratories, as well as supervising technical staff in supporting manufacturing, stability testing, release testing, clinical trials, regulatory submission and launch of small and large peptides and biologics therapeutics.
With 18 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly-owned global network, present in North America, Europe, and Asia, to deliver harmonized solutions to large pharmaceutical and biotechnology firms.
For further information, please contact:
SGS is the world's leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 97,000 employees, SGS operates a network of over 2,600 offices and laboratories around the world.